Lycia Therapeutics

Lycia Therapeutics

Edit info

  • Founded: 2020
  • Location: South SF, CA
  • Employee range: 1 - 10
  • Clinical stage: RD
  • Therapy area: Immunology conditions
  • Drug types: IMM, PN
  • Lead product: Undisclosed
  • Funding: $70M B Sep 2021; $50M Jun 2020
  • Investors: Versant Ventures


lyciatx.com

linkedin.com

job board


Drug notes:

Undisclosed RD pain

About:

Lycia Therapeutics is developing tools to degrade extracellular proteins exploiting knowledge of lysosomes. Lysosomes are cellular organelles that are hubs for protein degradation. Using their Lysosomal Targeting Chimera (LYTAC) platform, Lycia is hijacking the endogenous lysosomal trafficking shuttle to target the untapped extracellular proteome. The LYTAC platform can be extended to both board-based and tissue-specific targeting enabling several therapeutic modalities. Lycia is advancing an undisclosed discovery pipeline of novel LYTAC degraders for clearing protein aggregates and immune complexes, removal of circulating antibodies and degrading challenging membrane targets to treat autoimmune and inflammatory diseases.

Jobs:

Lycia Therapeutics
Senior Scientist I/II, Antibody Engineering (Phag...
South San Francisco|4 days ago
Apply
Lycia Therapeutics
Senior Scientist I, Biology
South San Francisco|22 days ago
Lycia Therapeutics
Scientist I, Antibody Design
South San Francisco|25 days ago
Lycia Therapeutics
Senior Accounting Manager / Assistant Controller
South San Francisco|40 days ago
Lycia Therapeutics
Laboratory Manager
South San Francisco|52 days ago
Lycia Therapeutics
Principal Scientist, Clinical Pharmacologist/Model...
South San Francisco|61 days ago
Lycia Therapeutics
Head of Regulatory Affairs
South San Francisco|82 days ago
Lycia Therapeutics
Research Associate II/Senior Research Associate I,...
South San Francisco|88 days ago


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com